PL3116887T3 - Ligandy węglowodanowe, które wiążą się z przeciwciałami igm przeciwko glikoproteinie związanej z mieliną - Google Patents

Ligandy węglowodanowe, które wiążą się z przeciwciałami igm przeciwko glikoproteinie związanej z mieliną

Info

Publication number
PL3116887T3
PL3116887T3 PL15709483T PL15709483T PL3116887T3 PL 3116887 T3 PL3116887 T3 PL 3116887T3 PL 15709483 T PL15709483 T PL 15709483T PL 15709483 T PL15709483 T PL 15709483T PL 3116887 T3 PL3116887 T3 PL 3116887T3
Authority
PL
Poland
Prior art keywords
bind
antibodies against
igm antibodies
associated glycoprotein
carbohydrate ligands
Prior art date
Application number
PL15709483T
Other languages
English (en)
Polish (pl)
Inventor
Beat Ernst
Ruben HERRENDORFF
Andreas Steck
Fan Yang
Original Assignee
Universität Basel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universität Basel filed Critical Universität Basel
Publication of PL3116887T3 publication Critical patent/PL3116887T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/207—Cyclohexane rings not substituted by nitrogen atoms, e.g. kasugamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F120/00—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride, ester, amide, imide or nitrile thereof
    • C08F120/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
    • C08F120/10—Esters
    • C08F120/34—Esters containing nitrogen, e.g. N,N-dimethylaminoethyl (meth)acrylate
    • C08F120/36—Esters containing nitrogen, e.g. N,N-dimethylaminoethyl (meth)acrylate containing oxygen in addition to the carboxy oxygen, e.g. 2-N-morpholinoethyl (meth)acrylate or 2-isocyanatoethyl (meth)acrylate
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F2/00—Processes of polymerisation
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
    • C08G69/08—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
    • C08G69/10—Alpha-amino-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/48—Polymers modified by chemical after-treatment
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/02—Food
    • G01N33/04—Dairy products
    • G01N33/06—Determining fat content, e.g. by butyrometer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/02—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates involving antibodies to sugar part of glycoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Polymers & Plastics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
PL15709483T 2014-03-13 2015-03-12 Ligandy węglowodanowe, które wiążą się z przeciwciałami igm przeciwko glikoproteinie związanej z mieliną PL3116887T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14159528 2014-03-13
PCT/EP2015/055140 WO2015136027A1 (fr) 2014-03-13 2015-03-12 Ligands glucidiques qui se lient aux anticorps igm contre la glycoprotéine associée à la myéline
EP15709483.0A EP3116887B1 (fr) 2014-03-13 2015-03-12 Ligands de type carbohydrate se liant aux anticorps de la glycoprotéine associée à la myéline

Publications (1)

Publication Number Publication Date
PL3116887T3 true PL3116887T3 (pl) 2021-09-06

Family

ID=50241299

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15709483T PL3116887T3 (pl) 2014-03-13 2015-03-12 Ligandy węglowodanowe, które wiążą się z przeciwciałami igm przeciwko glikoproteinie związanej z mieliną

Country Status (22)

Country Link
US (4) US9994605B2 (fr)
EP (2) EP3116887B1 (fr)
JP (1) JP6502374B2 (fr)
KR (1) KR20160132034A (fr)
CN (2) CN106103461B (fr)
AU (2) AU2015228870B2 (fr)
CA (1) CA2940579A1 (fr)
CY (1) CY1124344T1 (fr)
DK (1) DK3116887T3 (fr)
ES (1) ES2865148T3 (fr)
HR (1) HRP20210562T1 (fr)
HU (1) HUE054034T2 (fr)
IL (1) IL247355B (fr)
LT (1) LT3116887T (fr)
MX (1) MX2016011859A (fr)
PL (1) PL3116887T3 (fr)
PT (1) PT3116887T (fr)
RS (1) RS61722B1 (fr)
RU (1) RU2760005C2 (fr)
SG (1) SG11201607484RA (fr)
SI (1) SI3116887T1 (fr)
WO (1) WO2015136027A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3116887B1 (fr) 2014-03-13 2021-02-17 Universität Basel Ligands de type carbohydrate se liant aux anticorps de la glycoprotéine associée à la myéline
WO2017046172A1 (fr) 2015-09-16 2017-03-23 Universität Basel Ligands glucidiques se liant à des anticorps dirigés contre des glycoépitopes de glycosphingolipides
JP2020514414A (ja) * 2017-03-15 2020-05-21 ポリニューロン ファーマシューティカルズ アーゲー 糖結合タンパク質を隔離する糖ポリマー
EP3715374A1 (fr) 2019-03-23 2020-09-30 Ablevia biotech GmbH Composé de séquestration d'anticorps indésirables chez un patient
US11986536B2 (en) 2019-03-23 2024-05-21 Ablevia Biotech Gmbh Compound for the sequestration of undesirable antibodies in a patient
EP3715375A1 (fr) 2019-03-23 2020-09-30 Ablevia biotech GmbH Composé pour la prévention ou le traitement de la pré-éclampsie
EP3715376A1 (fr) 2019-03-23 2020-09-30 Ablevia biotech GmbH Composé pour la prévention ou le traitement de la myasthénie grave
EP4216990A1 (fr) 2020-09-23 2023-08-02 Ablevia biotech GmbH Composé pour la séquestration d'anticorps indésirables chez un patient
TW202228784A (zh) 2020-09-23 2022-08-01 奧地利商艾柏力維亞生技有限公司 用以於一患者中螯合非預期的抗ｐｅｇ抗體的化合物
MX2023003375A (es) 2020-09-23 2023-03-31 Ablevia Biotech Gmbh Compuesto para aumentar la eficacia de la terapia de sustitucion del factor viii.
AU2021347581A1 (en) 2020-09-23 2023-05-18 Ablevia Biotech Gmbh Compound for the prevention or treatment of autoantibody-mediated conditions
AU2021347583A1 (en) 2020-09-23 2023-05-25 Ablevia Biotech Gmbh Compound for increasing efficacy of viral vectors
JP2023543444A (ja) 2020-09-24 2023-10-16 アブレヴィア バイオテック ゲーエムベーハー 重症筋無力症の予防又は治療のための化合物
WO2023180502A1 (fr) 2022-03-24 2023-09-28 Ablevia Biotech Gmbh Composé pour augmentation de l'efficacité des virus oncolytiques

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2811494B2 (ja) 1990-03-14 1998-10-15 富士写真フイルム株式会社 キトサンまたはキチン化合物を含有するハロゲン化銀写真感光材料およびこれを用いるハロゲン化銀写真感光材料の処理方法
US5846951A (en) 1991-06-06 1998-12-08 The School Of Pharmacy, University Of London Pharmaceutical compositions
CA2110495A1 (fr) 1991-06-10 1992-12-23 Robert M. Ippolito Derives d'oligosaccharides immunosuppresseurs et tolerogenes
US5985578A (en) 1991-08-09 1999-11-16 Washington University Autoantibodies and their targets in the diagnosis of peripheral neuropathies
WO1993003375A1 (fr) 1991-08-09 1993-02-18 Washington University Auto-anticorps et leurs cibles utilises dans le diagnostic de neuropathies peripheriques
US6020140A (en) 1991-08-09 2000-02-01 Washington University Autoantibodies and their targets in the diagnosis of peripheral neuropathies
AU666128B2 (en) 1991-08-23 1996-02-01 Alberta Research Council Inc. Methods and compositions for attenuating antibody-mediated xenograft rejection in human recipients
EP0601417A3 (fr) 1992-12-11 1998-07-01 Hoechst Aktiengesellschaft Physiologiquement compatible et dégradable bloques de récepteur d'hydrate de carbone à base de polymère, procédé de leur préparation et leur utilisation
US5783693A (en) 1993-11-19 1998-07-21 The Regents Of The University Of California Methods for synthesizing sulfated disaccharide inhibitors of selectins
CA2133772A1 (fr) 1993-11-19 1995-05-20 Yuji Yamada Methode et reactif pour l'essai de glycoconjugues
DE19526675A1 (de) 1994-09-09 1996-03-14 Herbert Prof Dr Wiegandt Teststreifenanalyse zur Erfassung von autoallergen menschlichen Pathologien
FR2727117A1 (fr) 1994-11-18 1996-05-24 Geffard Michel Utilisation de conjugues de la polylysine pour la preparation de medicaments utiles dans le traitement des maladies neurodegeneratives et des affections degeneratives a caractere autoimmun
US5962434A (en) * 1995-08-25 1999-10-05 The Johns Hopkins University School Of Medicine Compounds for stimulating nerve growth
DE19531346A1 (de) * 1995-08-25 1997-02-27 Gsf Forschungszentrum Umwelt Arzneimittel zur Immuntherapie, enthaltend Antikörper, die spezifisch das MHCII-Antigen eines zu behandelnden Patienten erkennen
US5874411A (en) 1995-11-13 1999-02-23 Glycomed Incorporated Oligosaccharide glycosides having mammalian immunosuppresive and tolerogenic properties
JP3372551B2 (ja) 1995-11-21 2003-02-04 ノバルティス アクチエンゲゼルシャフト 多価ポリマー、その製造方法、および生物学的に活性な化合物の製造におけるその使用
US6491922B1 (en) 1996-02-09 2002-12-10 Cornell Research Foundation, Inc. Methods and compounds for treating autoimmune and vascular disease
IL132156A0 (en) 1997-04-18 2001-03-19 Novartis Ag Neoglycoproteins
FR2762602B1 (fr) 1997-04-28 1999-06-04 Inst Nat Sante Rech Med Moyens pour la detection precoce de pathologies auto-immunes inflammatoires
US6077681A (en) 1997-06-30 2000-06-20 Washington University Diagnosis of motor neuropathy by detection of antibodies
EP1015464A2 (fr) 1997-09-05 2000-07-05 Glycim Oy POLYLACTOSAMINES SYNTHETIQUES CONTENANT UN sLex DIVALENT ET SES METHODES D'UTILISATION
CA2326618A1 (fr) 1998-04-15 1999-10-21 Baxter International Inc. Inhibition d'anticorps xenoreactifs
WO1999053757A1 (fr) 1998-04-22 1999-10-28 Merck & Co., Inc. Fragments auto-antigenes, methodes et dosages
EP1094077A4 (fr) 1998-06-30 2003-04-02 Mochida Pharm Co Ltd Nouveau peptide lie par une chaine de sucres et similaire a la thrombomoduline
US6228598B1 (en) * 1998-10-02 2001-05-08 Washington University Antibodies to heparan sulfate glycosaminoglycans in the diagnosis of polyneuropathies
AU1729900A (en) 1998-11-16 2000-06-05 Genetics Institute Inc. The cxc chemokine h174 and methods for preventing damage to the nervous system
US6399578B1 (en) 1998-12-09 2002-06-04 La Jolla Pharmaceutical Company Conjugates comprising galactose α1,3 galactosyl epitopes and methods of using same
JP2002531531A (ja) 1998-12-09 2002-09-24 ラ ホヤ ファーマシューティカル カンパニー 循環している抗体を減少させるための方法および処方物
WO2000050447A1 (fr) 1999-02-24 2000-08-31 Acorda Therapeutics Peptides mimetiques d'epitope glucidique et utilisations correspondantes
DE19930177B4 (de) 1999-06-30 2007-02-08 Nikolai Vladimirovich Bovin Intermolekular assoziierende Verbindungen und deren Verwendung
KR20020047177A (ko) 1999-09-21 2002-06-21 아피나 이문테히닉 게엠베하 확장성 심근질환을 유발하는 자동항체를 제거하기 위한펩티드
US7332168B2 (en) 2000-08-22 2008-02-19 Micromet Ag Composition for the elimination of autoreactive B-cells
AU2001288431A1 (en) 2000-08-28 2002-03-13 The Trustees Of Columbia University In The City Of New York Detection of anti-glycolipid antibodies by latex agglutination assay
US7205382B2 (en) 2000-11-08 2007-04-17 Fresenius Medical Care Affina Gmbh Peptides, the production and use thereof for binding immunoglobulins
US6730487B2 (en) 2001-04-03 2004-05-04 Trustees Of Columbia University In The City Of New York Surface plasmon resonance biosensor for measurement of anti-glycolipid antibody levels in neuropathy
DE10127712A1 (de) 2001-06-07 2002-12-19 Torsten Witte Anwendung von IgM-Antikörpern gegen dsDNA beim systemischen Lupus erythematodes mit Nephritis
US20040176320A1 (en) 2001-06-29 2004-09-09 Jari Natunen Use of at least one glycoinhibitor substance
WO2003068822A2 (fr) 2002-02-13 2003-08-21 Micromet Ag Constructions (poly)peptidiques desimmunisees
CA2494422A1 (fr) 2002-08-02 2004-02-19 Glycominds Ltd. Procede de diagnostic de sclerose en plaques
AR040778A1 (es) 2002-08-06 2005-04-20 Glaxo Group Ltd Anticuerpos alterados o fragmentos funcionales que se unen a mag (glicoproteina asociada a mielina).
RU2303461C9 (ru) * 2002-08-06 2007-12-27 Глаксо Груп Лимитед Антитела против миелин-ассоциированного гликопротеина (mag)
US7175989B2 (en) * 2002-08-20 2007-02-13 Alan Pestronk Antibodies to trisulfated heparin disaccharide in painful sensory axonal neuropathy
US20040043431A1 (en) 2002-08-29 2004-03-04 Aristo Vojdani Diagnosis of multiple sclerosis and other demyelinating diseases
US20030049692A1 (en) 2002-09-16 2003-03-13 Norman Latov Detection of anti-glycolipid antibodies by latex agglutination assay
EP1589934B1 (fr) 2003-01-06 2015-09-23 Corixa Corporation Composés d'aminoalkyle glucosaminide phosphate et leur utilisation
WO2004065400A1 (fr) 2003-01-20 2004-08-05 Glykos Finland Oy Nouveaux epitopes de liaison a helicobacter pylori et utilisation desdits epitopes
JP5021309B2 (ja) 2003-10-16 2012-09-05 ステファン ジョン ラルフ 免疫調節性組成物およびその使用方法
WO2005054264A2 (fr) 2003-11-19 2005-06-16 Glycomimetics, Inc. Antagonistes glycomimetiques pour les selectines de type e et p
US20070258986A1 (en) 2003-11-19 2007-11-08 Govt of the US as represented by the secretary, Targeted Delivery System for Bioactive Agents
US7361644B2 (en) 2003-11-19 2008-04-22 Glycomimetics, Inc. Specific antagonist for both E- and P-selectins
US20050272097A1 (en) 2004-02-18 2005-12-08 Emanuel Calenoff Methods and compositions for detecting and treating autoimmune diseases
JP5139797B2 (ja) 2004-03-04 2013-02-06 プロジェン ファーマシューティカルズ リミテッド 硫酸化オリゴ糖誘導体
JP2008500372A (ja) 2004-05-26 2008-01-10 カリフォルニア インスティテュート オブ テクノロジー ニューロン成長の低分子刺激物質
CN101123990A (zh) 2004-10-01 2008-02-13 Mida科技有限公司 包含抗原和佐剂的纳米颗粒，和免疫原性结构
US9079765B2 (en) 2004-10-01 2015-07-14 Midatech Ltd. Nanoparticles comprising antigens and adjuvants, and immunogenic structures
WO2006068720A2 (fr) 2004-11-12 2006-06-29 The Brigham And Women's Hospital, Inc. Polypeptides de ligands de selectine des cellules hematopoietiques et procedes d'utilisation de ces polypeptides
US7884260B2 (en) 2005-06-14 2011-02-08 University Of Chicago Cell-based screen for agents useful for reducing neuronal demyelination or promoting neuronal remyelination
JP4619873B2 (ja) * 2005-06-20 2011-01-26 独立行政法人産業技術総合研究所 グルクロニル硫酸化２糖誘導体
WO2010002478A2 (fr) 2008-07-03 2010-01-07 University Of Georgia Research Foundation, Inc. Glycopeptide et son utilisation
EP1991204A2 (fr) 2006-02-24 2008-11-19 Novartis AG Microparticules contenant un polymère biodégradable et un polysaccharide cationique pour emploi dans des compositions immunogènes
WO2007120815A2 (fr) 2006-04-12 2007-10-25 The Regents Of The University Of California Procedes destines au traitement de troubles lymphocytaires par modulation de l'activite siglec
GB0610350D0 (en) 2006-05-25 2006-07-05 Univ Liverpool prevention and/or treatment of neuodegenerative disorders
US8420593B1 (en) 2006-06-16 2013-04-16 Landon C. G. Miller Compositions and methods for regulating membrane potential
US20090175792A1 (en) 2006-06-23 2009-07-09 Glycomimetics, Inc. Glycomimetic inhibitors of siglec-8
CA2662480C (fr) 2006-09-05 2016-11-08 Alexion Pharmaceuticals, Inc. Procedes et compositions de traitement de neuropathies induites par des antibiotiques
GB0622688D0 (en) 2006-11-14 2006-12-27 Diosamine Dev Corp Novel compounds
WO2008153615A2 (fr) 2007-03-07 2008-12-18 Ada Technologies, Inc. Microréseau de carbohydrate et nanoparticules conjuguées et procédés de fabrication
AU2008222678B2 (en) 2007-03-07 2013-01-17 The General Hospital Corporation Compositions and methods for the prevention and treatment of autoimmune conditions
WO2008151847A1 (fr) 2007-06-13 2008-12-18 Max-Delbrück-Centrum für Molekulare Medizin Peptides de liaison aux autoanticorps et leur utilisation pour le traitement de maladies vasculaires
WO2009017795A1 (fr) 2007-08-02 2009-02-05 Xanthus Pharmaceuticals, Inc. Composés d'indazole pour le traitement de troubles inflammatoires, de troubles démyélinisants et de cancers
CA2708246C (fr) 2007-12-05 2016-05-24 Wittycell Compositions et methodes destinees a ameliorer la reponse immunitaire aux antigenes
WO2009102820A2 (fr) 2008-02-11 2009-08-20 Government Of The U.S A., As Represented By The Secretary, Department Of Health And Human Services Substrats à base de sucres modifiés et procédés d’utilisation
US9119866B2 (en) 2008-04-08 2015-09-01 Huiru Wang Glycan-based drugs, therapies and biomarkers
JP5788312B2 (ja) 2008-04-11 2015-09-30 アルニラム ファーマスーティカルズ インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 標的リガンドをエンドソーム分解性成分と組み合わせることによる核酸の部位特異的送達
US7981625B2 (en) 2008-04-15 2011-07-19 The Board Of Trustees Of The Leland Stanford Junior University Prostate cancer glycan markers and autoantibody signatures
US20120190581A1 (en) 2009-08-25 2012-07-26 The Johns Hopkins University Detection of Auto-Antibodies to Specific Glycans as Diagnostic Tests for Autoimmune Diseases
US20110105389A1 (en) * 2009-10-30 2011-05-05 Hoveyda Hamid R Macrocyclic Ghrelin Receptor Antagonists and Inverse Agonists and Methods of Using the Same
GB0922066D0 (en) 2009-12-17 2010-02-03 Univ Belfast Modulator
WO2011101870A1 (fr) 2010-02-22 2011-08-25 Transgene Biotek Ltd. Protéines de fusion utilisées pour le traitement de la sclérose en plaques et d'autres maladies auto-immunes
JP6050227B2 (ja) 2010-06-11 2016-12-21 スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ 多価糖ペプチド構築物およびその使用
US9180182B2 (en) 2010-12-15 2015-11-10 Vereniging Voor Christelijk Wetenschappelijk Onder Wijs Method for suppressing an immune response
JP2014527985A (ja) 2011-09-23 2014-10-23 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 蠕虫由来グリカン含有化合物による脂肪肝疾患の治療方法
EP2698636A1 (fr) 2012-08-13 2014-02-19 Fundació Institut d'Investigació Biomèdica de Bellvitge Procédés et réactifs pour la prévention et/ou le traitement d'un rejet de greffe
KR101742406B1 (ko) 2012-08-16 2017-05-31 화이자 인코포레이티드 당접합 공정 및 조성물
EP2727597A1 (fr) 2012-11-06 2014-05-07 Centre National de la Recherche Scientifique (CNRS) Hydrogel sensible au glucose comprenant de l'acide hyaluronique (ha) greffé pba
SG11201508803RA (en) 2013-04-26 2015-11-27 Agency Science Tech & Res Tailoring multivalent interactions of biopolymers with a polyproline scaffol
WO2015007326A1 (fr) 2013-07-18 2015-01-22 Institut D'investigació Biomèdica De Bellvitge (Idibell) Agents comprenant une partie alpha-galactosyle terminale destinée à être utilisé dans la prévention et/ou le traitement de maladies inflammatoires
WO2015116775A1 (fr) 2014-01-30 2015-08-06 Trudeau Institute Nanoparticules pour stimulation immunitaire
EP3116887B1 (fr) 2014-03-13 2021-02-17 Universität Basel Ligands de type carbohydrate se liant aux anticorps de la glycoprotéine associée à la myéline
WO2017046172A1 (fr) 2015-09-16 2017-03-23 Universität Basel Ligands glucidiques se liant à des anticorps dirigés contre des glycoépitopes de glycosphingolipides

Also Published As

Publication number Publication date
US20210061838A1 (en) 2021-03-04
SG11201607484RA (en) 2016-10-28
SI3116887T1 (sl) 2021-06-30
HRP20210562T1 (hr) 2021-05-14
ES2865148T3 (es) 2021-10-15
CA2940579A1 (fr) 2015-09-17
DK3116887T3 (da) 2021-04-26
US20180327438A1 (en) 2018-11-15
AU2015228870A1 (en) 2016-09-29
US20170022239A1 (en) 2017-01-26
AU2019271964B2 (en) 2021-07-01
AU2019271964A1 (en) 2019-12-19
CY1124344T1 (el) 2022-07-22
MX2016011859A (es) 2017-05-12
NZ724236A (en) 2021-06-25
RU2760005C2 (ru) 2021-11-22
CN106103461B (zh) 2019-05-10
US20220185838A1 (en) 2022-06-16
LT3116887T (lt) 2021-05-25
WO2015136027A1 (fr) 2015-09-17
HUE054034T2 (hu) 2021-08-30
US10662212B2 (en) 2020-05-26
EP3915999A1 (fr) 2021-12-01
IL247355A0 (en) 2016-11-30
JP6502374B2 (ja) 2019-04-17
US11220523B2 (en) 2022-01-11
RU2016134035A (ru) 2018-04-13
EP3116887A1 (fr) 2017-01-18
AU2015228870B2 (en) 2019-08-29
CN106103461A (zh) 2016-11-09
EP3116887B1 (fr) 2021-02-17
JP2017509629A (ja) 2017-04-06
RS61722B1 (sr) 2021-05-31
RU2016134035A3 (fr) 2018-10-25
US9994605B2 (en) 2018-06-12
KR20160132034A (ko) 2016-11-16
IL247355B (en) 2020-09-30
PT3116887T (pt) 2021-04-30
CN110204582A (zh) 2019-09-06

Similar Documents

Publication Publication Date Title
IL247355B (en) Carbohydrate ligands that bind to igm antibodies against myelin-associated glycoprotein
IL285287B1 (en) Antibodies to tigit
IL282403B1 (en) Antibodies against pd-1
IL284336B (en) Treatment using antibodies that bind to ctla4
HK1252262A1 (zh) 結合抗糖鞘脂糖蛋白表位抗體的碳水化合物配體
IL261188A (en) Antibodies against tigit
IL251963A0 (en) Anti-1-pd antibodies
HK1217958A1 (zh) 四價雙特異性抗體
IL272042A (en) Antibodies that bind IL-23
HK1256300A1 (zh) 特異性地結合至tl1a的抗體
AP2015008709A0 (en) Anti-tnf-anti-il-17 bispecific antibodies
SG11201604503XA (en) Cytotoxic antibody
GB201419080D0 (en) Anti-PD-1 antibodies
GB201419087D0 (en) Anti-PD-1 antibodies